MapLight Therapeutics closed its IPO, raising $296.3 million, selling 16.9 million shares at $17 each, trading under "MPLT."
Quiver AI Summary
MapLight Therapeutics, a biopharmaceutical company focused on central nervous system disorders, announced the successful completion of its initial public offering, selling 16,962,500 shares of common stock at $17.00 per share, which includes an underwriters' option for additional shares. The company also conducted a private placement of 476,707 shares, raising gross proceeds of $296.3 million from both offerings. The shares began trading on the Nasdaq under the symbol "MPLT" on October 27, 2025. MapLight develops treatments for severe neurological conditions, and its leading candidate, ML-007C-MA, is currently in Phase 2 trials for schizophrenia and Alzheimer's disease psychosis.
Potential Positives
- MapLight Therapeutics successfully closed its initial public offering, raising $296.3 million, which will provide substantial funding for its clinical development programs.
- The offering was well-received, as it included the full exercise of the underwriters' option to purchase additional shares, indicating strong demand.
- The company's shares began trading on the Nasdaq Global Select Market under the symbol "MPLT," enhancing its visibility and accessibility to investors.
Potential Negatives
- MapLight's reliance on a private placement of shares that was not registered under the Securities Act may raise concerns about transparency and regulatory compliance among investors.
- The announcement of the IPO implies a transition phase for MapLight, which could indicate financial pressures or the need for significant capital investment to support their ongoing clinical trials.
- The company's focus on central nervous system disorders could be seen as a risky investment due to the high failure rates and long timelines typically associated with drug development in this area.
FAQ
What is the recent IPO price for MapLight Therapeutics?
The initial public offering price for MapLight Therapeutics was $17.00 per share.
How many shares were offered in the IPO by MapLight?
MapLight offered a total of 16,962,500 shares in its initial public offering.
Where can I find the prospectus for MapLight's offering?
The final prospectus can be obtained from Morgan Stanley, Jefferies, Leerink Partners, or Stifel.
What is MapLight Therapeutics focused on?
MapLight Therapeutics is focused on developing treatments for debilitating central nervous system disorders.
What is the lead product candidate for MapLight?
MapLight's lead product candidate is ML-007C-MA, targeting schizophrenia and Alzheimer's disease psychosis.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
SAN FRANCISCO and BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today announced the closing of its initial public offering of 16,962,500 shares of common stock at an initial public offering price of $17.00 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 2,212,500 shares of common stock.
In addition to the shares sold in the initial public offering, MapLight announced the closing of the concurrent sale of 476,707 shares of common stock at the initial public offering price per share in a private placement to affiliates of Goldman Sachs & Co. LLC, including certain investment funds managed by Goldman Sachs & Co. LLC. The sale of the shares of common stock in the private placement was not registered under the Securities Act of 1933, as amended (the “Securities Act”).
The gross proceeds to MapLight from the initial public offering and the concurrent private placement, before deducting underwriting discounts and commissions and offering expenses, were $296.3 million. All of the shares of common stock were offered by MapLight.
The shares began trading on the Nasdaq Global Select Market on October 27, 2025 under the symbol “MPLT.”
Morgan Stanley, Jefferies, Leerink Partners and Stifel acted as joint book-running managers for the offering.
A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission, and became automatically effective on October 25, 2025 pursuant to Section 8(a) of the Securities Act. The offering of the shares is being made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at [email protected] ; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at [email protected] ; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, or by email at [email protected] .
This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of that state or jurisdiction.
About MapLight
MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders. The company was founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. MapLight’s lead product candidate, ML-007C-MA, is an oral, extended-release, fixed-dose combination of an investigational M1/M4 muscarinic agonist, ML-007, co-formulated with a peripherally acting anticholinergic. ML-007C-MA is currently being evaluated in Phase 2 clinical trials for the treatment of schizophrenia and Alzheimer's disease psychosis.
For investor inquiries: [email protected]
For media inquiries: [email protected]
